The paradox of immunotherapy in NASH-HCC

Signal Transduct Target Ther. 2021 Jun 10;6(1):228. doi: 10.1038/s41392-021-00654-9.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Carcinoma, Hepatocellular*
  • Humans
  • Immunotherapy
  • Liver Neoplasms* / therapy
  • Non-alcoholic Fatty Liver Disease* / therapy